UNSPSC 51111805: Goserelin

This classification denotes a gonadotropin-releasing hormone analog with the molecular formula C59H84N18O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0F65R8P09N, chemically known as luteinizing hormone-releasing factor (pig), 6-(o-(1,1-dimethylethyl)-d-serine)-10-deglycinamide-, 2-(aminocarbonyl)hydrazide but generally known as goserelin, which bears US NIH Compound Identifier 47725. European Medicines Agency schedules Goserelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07962MIG.

UNSPSC 51111805 Goserelin, a Commodity code, covers pharmaceutical products supplied through state and local cooperative purchasing vehicles and multi-source drug procurement programs. State and local governments buy generic pharmaceuticals and over-the-counter products under this code through established wholesaler networks, with procurement centered on manufacturers capable of supplying products with specific National Drug Codes (NDC), managing compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and maintaining relationships with authorized pharmaceutical distributors. The issuing bodies soliciting under this code include state cooperative purchasing alliances serving multiple states and their constituent local government facilities, such as health departments, correctional institutions, and public health agencies across participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates submission of detailed product information including NDC codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations. Products must be available in the marketplace by May 15, 2026, with contract awards effective July 1, 2026, and the contract term runs two years for new vendors with optional extensions at MMCAP's discretion. Evaluation criteria are weighted toward price competitiveness (75 percent), with remaining weight assigned to fixed pricing (10 percent), compliance with administrative data formats (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability coverage of at least $5 million per occurrence and comply with performance penalties of $200 to $1,500 per violation for late reporting or missed onboarding timelines.